Serum Monocyte Fraction of White Blood Cells is Increased in Patients with High Gleason Score Prostate Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 9

PMID 27823973

Citations 20

Authors

Takuji Hayashi

Kazutoshi Fujita

Go Tanigawa

Atsunari Kawashima

Akira Nagahara

Takeshi Ujike

Motohide Uemura

Tetsuya Takao

Seiji Yamaguchi

Norio Nonomura

Affiliations

Soon will be listed here.

Abstract

Systemic inflammation and immune responses are reported to be associated with progressive prostate cancer. In this study, we explored which among the fractions of white blood cell (WBC) and C-reactive protein (CRP) level were associated with high Gleason score prostate cancer. Prostate needle biopsy was performed in 966 men with suspicion of prostate cancer. We assessed age, serum prostate-specific antigen (PSA), prostate volume, WBC count, fractions of WBCs (neutrophils, lymphocytes, monocytes, basophils, and eosinophils), and CRP level before biopsy for associations with biopsy findings. Among all men, 553 (57.2%) were positive for prostate cancer including 421 with high Gleason score cancer (Gleason score ≥7). Age, PSA, PSA density (PSAD), serum monocyte fraction of WBC, monocyte-to-lymphocyte ratio (MLR), and CRP were significantly associated with high Gleason score cancer (p<0.01). Multivariate analysis showed that age, PSA, PSAD, and serum monocyte fraction were significantly associated with high Gleason score prostate cancer (p <0.01). In 571 patients with PSA of <10 ng/ml, age, PSA, PSAD, serum WBC count, neutrophil fraction, monocyte fraction, and MLR were significantly associated with high Gleason score prostate cancer (p<0.05). Multivariate analysis showed that age, PSAD, and serum monocyte fraction were significantly associated with high Gleason score prostate cancer (p<0.01). The monocyte fraction of WBCs was increased in patients with high Gleason score prostate cancer, suggesting an interaction of monocytes with the progression of prostate cancer.

Citing Articles

NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.

Fanijavadi S, Hansen T, Zedan A Biomolecules. 2025; 15(2).

PMID: 40001576 PMC: 11852595. DOI: 10.3390/biom15020273.

Causal association of peripheral immune cell counts with risk of prostate cancer: insights from bidirectional Mendelian randomization.

Ren X, Zhang L, Wang K, Li F Front Oncol. 2024; 14:1374927.

PMID: 39678517 PMC: 11638012. DOI: 10.3389/fonc.2024.1374927.

Immunome profiling in prostate cancer: a guide for clinicians.

San-Jose Manso L, Alfranca A, Moreno-Perez I, Ruiz-Vico M, Velasco C, Toquero P Front Immunol. 2024; 15:1398109.

PMID: 39635522 PMC: 11614818. DOI: 10.3389/fimmu.2024.1398109.

Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio.

Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A BMC Urol. 2024; 24(1):226.

PMID: 39407194 PMC: 11481316. DOI: 10.1186/s12894-024-01617-2.

Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study.

Wang L, Li X, Liu M, Zhou H, Shao J Front Cell Dev Biol. 2024; 12:1372731.

PMID: 38645410 PMC: 11026607. DOI: 10.3389/fcell.2024.1372731.

References

Spary L, Salimu J, Webber J, Clayton A, Mason M, Tabi Z . Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology. 2015; 3(9):e955331. PMC: 4292218. DOI: 10.4161/21624011.2014.955331. View

Polascik T, Oesterling J, Partin A . Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999; 162(2):293-306. DOI: 10.1016/s0022-5347(05)68543-6. View

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L . The origin and function of tumor-associated macrophages. Immunol Today. 1992; 13(7):265-70. DOI: 10.1016/0167-5699(92)90008-U. View

Rocha P, Morgan C, Templeton A, Pond G, Naik G, Sonpavde G . Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat. 2014; 37(12):772-6. DOI: 10.1159/000369545. View

Liu Z, Chu L, Fang J, Zhang X, Zhao H, Chen Y . Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014; 16(3):467-71. PMC: 4023380. DOI: 10.4103/1008-682X.123686. View

van der Kwast T, Bubendorf L, Mazerolles C, Raspollini M, van Leenders G, Pihl C . Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch. 2013; 463(3):367-77. DOI: 10.1007/s00428-013-1466-5. View

Chen R, Rumble R, Loblaw D, Finelli A, Ehdaie B, Cooperberg M . Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(18):2182-90. DOI: 10.1200/JCO.2015.65.7759. View

Amin M, Lin D, Gore J, Srigley J, Samaratunga H, Egevad L . The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists,.... Arch Pathol Lab Med. 2014; 138(10):1387-405. DOI: 10.5858/arpa.2014-0219-SA. View

Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N . Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget. 2015; 6(31):32169-76. PMC: 4741667. DOI: 10.18632/oncotarget.5081. View

10.

Yamada Y, Sakamoto S, Sazuka T, Goto Y, Kawamura K, Imamoto T . Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men. Int J Urol. 2015; 23(1):49-54. DOI: 10.1111/iju.12952. View

11.

Wang L, Long W, Li P, Lin Y, Liang Y . An Elevated Peripheral Blood Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma. PLoS One. 2015; 10(5):e0126269. PMC: 4423962. DOI: 10.1371/journal.pone.0126269. View

12.

Lippi G, Montagnana M, Guidi G, Plebani M . Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?. Ann Med. 2009; 41(7):480-9. DOI: 10.1080/07853890903156468. View

13.

Saini S . PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr). 2016; 39(2):97-106. PMC: 4821699. DOI: 10.1007/s13402-016-0268-6. View

14.

Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M . Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2010; 107(12):1918-22. DOI: 10.1111/j.1464-410X.2010.09804.x. View

15.

Lindholm P, Sivapurapu N, Jovanovic B, Kajdacsy-Balla A . Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity. J Clin Cell Immunol. 2015; 6(2). PMC: 4548876. DOI: 10.4172/2155-9899.1000308. View

16.

Fujita K, Hayashi T, Matsuzaki K, Nakata W, Masuda M, Kawashima A . Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer. Oncotarget. 2016; 7(35):56643-56649. PMC: 5302941. DOI: 10.18632/oncotarget.10987. View

17.

Nakajima K, Heilbrun L, Smith D, Hogan V, Raz A, Heath E . The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget. 2016; 8(11):17643-17650. PMC: 5392275. DOI: 10.18632/oncotarget.12620. View

18.

Fujita K, Hosomi M, Nakagawa M, Tanigawa G, Imamura R, Uemura M . White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol. 2013; 21(3):308-12. DOI: 10.1111/iju.12243. View

19.

Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N . Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis. 2012; 15(4):386-90. DOI: 10.1038/pcan.2012.27. View

20.

Hoogland A, Bottcher R, Verhoef E, Jenster G, van Leenders G . Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget. 2016; 7(25):37846-37856. PMC: 5122354. DOI: 10.18632/oncotarget.9344. View